Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 13;13(11):e19549.
doi: 10.7759/cureus.19549. eCollection 2021 Nov.

Duration of Dual Antiplatelet Therapy After Stent Implantation, Still an Enigma: A Systematic Review of Randomized Clinical Trials

Muhammad Bin Aslam Zahid  1   2   3 , Marrium S Memon  3 , Mamatha Tappiti  3 , Vignarth Shantha Kumar  4 , Armaan M Nazir  3 , Bhavya Koganti  3 , Kunal Gupta  3 , Jihan A Mostafa  5
Affiliations
Review

Duration of Dual Antiplatelet Therapy After Stent Implantation, Still an Enigma: A Systematic Review of Randomized Clinical Trials

Muhammad Bin Aslam Zahid et al. Cureus. .

Abstract

Dual antiplatelet therapy (DAPT) is used in patients after drug-eluting stent (DES) implantation to prevent stent thrombosis and ischemic events. The ideal duration of DAPT in patients after DES implantation is a topic of debate among clinicians. In the past, many research studies were published related to an optimal duration of DAPT after DES implantation. In common practice, DAPT should be continued for one year or more after percutaneous coronary intervention (PCI) followed by DES implantation. The duration of DAPT is significant as long-term DAPT has beneficial effects but is associated with side effects like bleeding. On the other hand, short-term DAPT has a lower risk of bleeding, but it increases the rate of stent thrombosis or ischemic events. Our aim in this systematic review is to solve the dispute regarding the duration of DAPT after DES implantation. So, we tried to find the efficacy and safety of short-term (six months) DAPT by compiling data from randomized control trials (RCTs). We conducted this systematic review following the guidelines defined in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. We searched for our data from multiple databases like PubMed, Web of Science, ScienceDirect, and Google Scholar. We reviewed 10964 studies and then applied inclusion/exclusion criteria and PRISMA guidelines. Finally, we were left with only 21 studies regarding the optimal duration of DAPT after DES implantation. Our systematic review will help determine the non-inferiority of short-term (six months) DAPT to long-term (12 months) DAPT. Furthermore, we also noticed with short-term (six months) DAPT, there was decreased incidence of bleeding as compared to DAPT for long-term. But more studies were required to establish the safety and effectiveness of short-term (six months) DAPT compared to long-term (12 months) DAPT in patients after DES implantation.

Keywords: : acute coronary syndrome; acute myocardial infraction; drug eluting stent; dual anti-platelet therapy; primary percutaneous coronary intervention (pci); stent graft thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. The PRISMA Flow Diagram of the Systematic Review
PRISMA: preferred reporting items for systematic reviews and meta-analyses
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention: About underlying cause of death, 1999-2019. [ Aug; 2021 ];https://wonder.cdc.gov/ucd-icd10.html 2018 10
    1. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Benjamin EJ, Muntner P, Alonso A, et al. Circulation. 2019;139:0. - PubMed
    1. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Leon MB, Baim DS, Popma JJ, et al. N Engl J Med. 1998;339:1665–1671. - PubMed
    1. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Ope Hea. 2017;4:0. - PMC - PubMed
    1. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. Costa F, Van Klaveren D, Feres F, et al. J Am Coll Cardiol. 2019;73:741–754. - PubMed

LinkOut - more resources